Compare WSO & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSO | JAZZ |
|---|---|---|
| Founded | 1945 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 16.1B |
| IPO Year | 1994 | 2007 |
| Metric | WSO | JAZZ |
|---|---|---|
| Price | $305.78 | $242.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $399.00 | $217.57 |
| AVG Volume (30 Days) | 444.5K | ★ 869.5K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 5.92 | ★ 7.17 |
| Revenue | ★ $7,239,290,000.00 | $1,618,693,000.00 |
| Revenue This Year | $3.02 | $6.22 |
| Revenue Next Year | $5.20 | $7.68 |
| P/E Ratio | $51.13 | ★ $33.59 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $295.75 | $124.50 |
| 52 Week High | $459.00 | $266.38 |
| Indicator | WSO | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 37.43 | 43.33 |
| Support Level | $298.21 | $240.63 |
| Resistance Level | $321.13 | $242.66 |
| Average True Range (ATR) | 8.44 | 6.58 |
| MACD | 1.32 | -0.68 |
| Stochastic Oscillator | 2.37 | 20.27 |
Watsco is the largest HVAC and refrigeration products distributor in North America with approximately 13% market share. The company primarily operates in the United States (90% of revenue) with significant exposure in the Sunbelt states. Watsco also has operations in Canada, Latin America, and the Caribbean. The company's customer base comprises more than 120,000 dealers and contractors serving the replacement and new-construction HVAC/R markets for residential and light-commercial applications. As much as 20% of residential HVAC units are distributed through Watsco in any given year. Revenue is approximately 75%-80% residential HVAC and 20%-25% commercial, with relatively small exposure to more complex "applied" solutions.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.